Neurons containing orexin or melanin concentrating hormone reciprocally regulate wake and sleep by Roda Rani Konadhode et al.
SYSTEMS NEUROSCIENCE
REVIEW ARTICLE
published: 08 January 2015
doi: 10.3389/fnsys.2014.00244
Neurons containing orexin or melanin concentrating
hormone reciprocally regulate wake and sleep
Roda Rani Konadhode1, Dheeraj Pelluru1 and Priyattam J. Shiromani1,2*
1 Departments of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA
2 Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
Edited by:





Matthew Philip Parsons, University
of British Columbia, Canada
*Correspondence:
Priyattam J. Shiromani, Ralph H.
Johnson VA Medical Center and
Departments of Psychiatry and
Behavioral Sciences, Medical
University of South Carolina, 114
Doughty Street, Room 404,
Charleston, SC 29425, USA
e-mail: shiroman@musc.edu
Neurons containing orexin (hypocretin), or melanin concentrating hormone (MCH) are
intermingled with each other in the perifornical and lateral hypothalamus. Each is a separate
and distinct neuronal population, but they project to similar target areas in the brain.
Orexin has been implicated in regulating arousal since loss of orexin neurons is associated
with the sleep disorder narcolepsy. Microinjections of orexin into the brain or optogenetic
stimulation of orexin neurons increase waking. Orexin neurons are active in waking and
quiescent in sleep, which is consistent with their role in promoting waking. On the other
hand, the MCH neurons are quiet in waking but active in sleep, suggesting that they could
initiate sleep. Recently, for the first time the MCH neurons were stimulated optogenetically
and it increased sleep. Indeed, optogenetic activation of MCH neurons induced sleep in
both mice and rats at a circadian time when they should be awake, indicating the powerful
effect that MCH neurons have in suppressing the wake-promoting effect of not only
orexin but also of all of the other arousal neurotransmitters. Gamma-Aminobutyric acid
(GABA) is coexpressed with MCH in the MCH neurons, although MCH is also inhibitory.
The inhibitory tone of the MCH neurons is opposite to the excitatory tone of the orexin
neurons. We hypothesize that strength in activity of each determines wake vs. sleep.
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EARLY HISTORY OF SLEEP RESEARCH
In the last 100 years significant progress has been made in
identifying the neurons that wake us up and make us fall
asleep. The history behind the research effort is quite fascinat-
ing and involves the influenza epidemic of 1918. It was during
that epidemic that a young Viennese physician named Baron
von Economo concluded that sleep and waking were gener-
ated from specific areas of the brain (Economo, 1930). von
Economo’s conclusions were revolutionary since at that time it
was believed that sleep occurred because people simply closed
their eyes. Von Economo performed autopsies on some of the
patients who had succumbed to the disease and from his obser-
vations he concluded that there was a region in the rostral
part of the hypothalamus that was responsible for sleep and
a region in the posterior hypothalamus that was responsible
for wake.
At that time many distinguished scientists were intrigued
by sleep and wake centers in the brain and were actively
involved in trying to unravel the mysteries of the sleeping
brain. One such investigator was Walle Nauta who was con-
ducting his studies during the height of the Second World
War in Holland. He wanted to determine whether rats with
lesions in the brain, similar to those found in humans by von
Economo, could have changes in sleep and wake. He did not
have an electroencephalogram to record brain activity, but solely
from behavioral observations he came to the same conclusion
as von Economo (Nauta, 1946). Moruzzi and Magoun then
showed that a sedated animal without any lesions could be
aroused by electrically stimulating the brainstem reticular core
(Moruzzi and Magoun, 1949).
DISCOVERY OF REM SLEEP
Everything changed in 1953 when REM sleep was discovered
(Aserinsky and Kleitman, 1953). The discovery was made by
Eugene Aserinsky, a graduate student in the laboratory of
Nathaniel Kleitman at the University of Chicago. Aserinsky’s
doctoral thesis was to describe the pattern of eye movements in
infants. He connected his 8 year-old son Armond to an EEG
machine and noticed that at various points in the night, the
pattern of the EEG activity and the eye movements began to
resemble what one would notice during waking (Brown, 2003).
He rushed in to the room to see if the boy was awake and much
to his surprise he was fast asleep, but yet the EEG looked as if
he was awake. He could not readily explain why there would be
a sudden shift in the EEG to a waking EEG even though the
boy was behaviorally asleep. His mentor was equally skeptical
and both felt that they were recording some sort of artifact.
Aserinsky methodically eliminated all doubts and once Kleitman
was convinced, they published their paper in the journal Science.
It was a simple paper that described regularly occurring periods
of eye movements every 90 min or so, and that these periods
occurred with a waking EEG.
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Their discovery was a landmark in neuroscience research
because it clearly showed for the first time that every 90 min the
brain awakened itself during sleep. This new sleep state was called
rapid eye movement sleep or REM sleep because of the occurrence
of eye movements. The other phase of sleep was called non-REM
sleep. REM sleep represents a paradox in that behaviorally one can
see that the person is asleep, yet the pattern of the EEG activity
resembles what is seen during waking. Another name for REM
sleep is “paradoxical sleep”. Indeed, it is now very clear that the
activity of the brain during a REM sleep episode is similar to
waking.
Very quickly other researchers began to investigate this new
phase of sleep and it was discovered that it was present in lower
animal species as well. By the late 1950’s a French neuroscien-
tist, Michel Jouvet, determined that REM sleep was generated
from the brainstem (Jouvet, 1962, 1972). We now know that
there are neurons in the pontine brainstem that are respon-
sible for generating REM sleep (Kaur et al., 2009). However
the signal that initiates REM sleep emanates from the hypotha-
lamus. In other words, we have now come full circle to von
Economo.
OREXIN, WAKING AND NARCOLEPSY
In 1998 two independent groups using different approaches
discovered orexin (also known as hypocretin) (de Lecea et al.,
1998; Sakurai et al., 1998). The distribution of orexin-containing
neurons has been plotted in the mouse, rat (de Lecea et al.,
1998; Peyron et al., 1998; Sakurai et al., 1998; Nambu et al.,
1999) and humans (Elias et al., 1998; Thannickal et al., 2000),
and we have plotted its distribution in the cat (Wagner et al.,
2000). Orexin neurons project to virtually the entire brain and
spinal cord, providing especially heavy innervation to regions
implicated in the regulation of wakefulness such as the tubero-
mammillary nucleus (TMN) and the locus coeruleus (LC;
Peyron et al., 1998). There are two orexin receptors (orexin-
1 and orexin-2 receptors; or hypocretin 1 and hypocretin-2
receptors) and their distribution in the brain has been deter-
mined (Greco and Shiromani, 2001; Marcus et al., 2001).
These receptors are especially heavy in areas implicated in
wakefulness such as the LC (mainly orexin-1 receptors), TMN
(mainly orexin-2 receptors), the dorsal raphe, and the basal
forebrain.
In 1999 these peptides were linked to narcolepsy, a sleep
disorder characterized by excessive daytime sleepiness and sud-
den muscle paralysis (called cataplectic attacks). Canines with
narcolepsy were found to have a mutation in the orexin-2
(hypocretin-2) receptor (Lin et al., 1999) while mice lacking
the orexin peptide (Chemelli et al., 1999) or the neurons con-
taining orexin (hypocretin) (Hara et al., 2001) displayed behav-
ioral and EEG signs of narcolepsy. Human narcoleptics have
low to negligible levels of orexin-A in the cerebrospinal fluid
(CSF) (Nishino et al., 2000), indicating a defect in release of the
peptide, or actual loss of the orexin neurons. That same year,
examination of post-mortem tissue revealed massive loss of the
orexin neurons in the brains of subjects with narcolepsy (Peyron
et al., 2000; Thannickal et al., 2000). In narcolepsy the orexin
neurons are likely destroyed since other markers that colocalize
with orexin, such as dynorphin and NARP, are also absent in
humans with narcolepsy (Blouin et al., 2005; Crocker et al.,
2005).
WHAT KILLS OREXIN NEURONS IN NARCOLEPSY?
It is not clear what kills the orexin neurons. Human narcolepsy is
considered to be an autoimmune disease because of its linkage
with the human leukocyte antigen-DQB1∗0602 (Mignot et al.,
1995, 1997). There appears to be a link with influenza based on
the evidence that the influenza epidemic of 1918 caused people
to be excessively sleepy and those that died were found to have
lesions in the posterior hypothalamus (Economo, 1930). Indeed,
in 2009 an H1N1 influenza strain appeared and a vaccine was
created to prevent a global epidemic. The vaccine contained
three genes derived from H1N1 and batches were made with
and without adjuvants. By 2010 there emerged a cluster of
cases in Europe, especially children, who displayed sudden-onset
narcolepsy. An initial report (De la Herrán-Arita et al., 2013)
suggesting a possible mimicry between epitopes on endogenous
orexin (hypocretin) and the influenza protein has not been
borne out.
OREXIN, AROUSAL AND CATAPLEXY
Orexin neurons discharge only during waking, especially with
movement (Lee et al., 2005; Mileykovskiy et al., 2005). Thus, it
is not surprising that when these neurons are lost, as in nar-
colepsy, patients have excessive daytime sleepiness and frequent
sleep attacks. Narcoleptic patients also suddenly lose motor tone
and collapse, especially in response to emotional stimuli, such
as laughter or anger (Aldrich, 1991). These bouts are referred
to as cataplexy. Canines with narcolepsy have a mutation in
the orexin-2 (hypocretin-2) receptor and display cataplexy (Lin
et al., 1999). The orexin control of muscle tone is through a
specific pathway in the pons and medulla (Peever et al., 2014).
Mice that lack orexin (Chemelli et al., 1999) or the orexin
neurons (Hara et al., 2001) display all of the symptoms of
narcolepsy. Mice that lack the orexin-1 (hypocretin-1) receptor
have excessive sleepiness, albeit cataplexy is not as severe as
the ligand knockouts (Willie et al., 2003). Mice with deletions
of the orexin-2 receptor have a severe cataplexy as the ligand
knockouts (Kalogiannis et al., 2011). We have linked orexin-B
to the neurotoxin saporin to kill the orexin neurons and find
that the rats display narcoleptic symptoms (Gerashchenko et al.,
2001).
Because the orexin neurons are nestled with neurons that
control other behaviors new genetically engineered tools are nec-
essary to selectively manipulate only the orexin neurons. These
new tools include optogenetics and DREDD (Designer Recep-
tors Excitated by Designer Drugs). Optogenetic activation of the
orexin neurons produces arousal (Adamantidis et al., 2007; Carter
et al., 2010; Tsunematsu et al., 2011) and inhibition with DREDD
produces sleep (Sasaki et al., 2011).
Based on the converging evidence from human nar-
colepsy, neuroanatomy, electrophysiology, pharmacology, knock-
out (ligand and receptor), and the new optogenetic/DREDD
data a network model has emerged that hypothesizes that the
orexin neurons regulate arousal and muscle tone by activating
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downstream arousal neurons in the basal forebrain, TMN, dorsal
raphe, and the LC.
OREXIN GENE TRANSFER TO RESCUE NARCOLEPSY SYMPTOMS
We pioneered the use of gene therapy to rescue narcolepsy
symptoms in mouse models of the disease. In three studies
we reinserted the gene for orexin into surrogate neurons and
convincingly demonstrated that it decreased cataplexy (Liu et al.,
2008, 2011; Blanco-Centurion et al., 2013). We demonstrated that
there is site-specificity in that the orexin gene must be inserted
into surrogate neurons that are part of the circuit regulating
cataplexy. Moreover, the surrogate neurons must be active during
the cataplexy bout because that would release the orexin onto
target neurons and stabilize the circuit (Bourgin et al., 2000;
Huang et al., 2001). Another group transferred the gene for the
orexin receptors into mice that lacked both the orexin receptors
(Hasegawa et al., 2014). Reinsertion of the orexin-2 receptor
specifically into the serotonergic dorsal raphe neurons decreased
cataplexy while insertion of the orexin-1 receptor only in nora-
drenergic LC neurons increased waking. Such, mapping studies
using genetically engineered tools are elucidating specific circuits
regulating sleep and wake.
SLEEP-ACTIVE NEURONS
Much of the research in sleep neurobiology has focused on
the arousal neurons. However, what shuts-off the arousal neu-
rons so that sleep can ensue? One possibility is that dur-
ing waking endogenous factors such as adenosine, cytokines
and prostaglandins accumulate and inhibit the waking neurons
(Krueger et al., 2011). Glia may also release adenosine to increase
sleep pressure (Halassa et al., 2009). The decrease in activity of
arousal neurons allows sleep-active neurons to become active
and generate sleep. These sleep-active neurons begin to fire in
drowsiness and then increase their firing during non-REM sleep
and REM sleep (Jones, 2011). The increase in activity of the
sleep-active neurons potently shuts off the wake-active neurons
to induce sleep. Sleep-active neurons have been identified in the
preoptic area (Sherin et al., 1996), the cortex (Gerashchenko
et al., 2008), and in the lateral hypothalamus (Hassani et al.,
2009).
THE GALANIN-POSITIVE SLEEP-ACTIVE NEURONS IN THE PREOPTIC
AREA
The preoptic area was initially identified by von Economo and
Nauta as being important for sleep since discrete lesions of
this region produced insomnia. It is now known that stimu-
lation of this region by small electrical currents, warming or
by pharmacological means will produce sleep (McGinty and
Szymusiak, 2000). c-Fos, an immediate early gene and a marker
of neuronal activity, has helped to identify the phenotype of
the sleep-active neurons and define the region and the connec-
tion to arousal neurons (Sherin et al., 1996). c-Fos expressing
sleep-active neurons are present in the ventral lateral preop-
tic area (VLPO; Sherin et al., 1996) and the median preoptic
area (MnPN; Alam et al., 1995; Szymusiak et al., 1998; Gong
et al., 2000; Suntsova et al., 2002). These sleep-active neurons
contain Gamma-Aminobutyric acid (GABA) and galanin and
are inhibitory to major arousal populations (Chou et al., 2002).
The VLPO neurons are inhibited by acetylcholine, serotonin and
norepinephrine (NE), but are unaffected by histamine (Gallopin
et al., 2000).
Electrophysiology studies have confirmed that neurons in
the VLPO and MnPN begin to fire during drowsiness and
peak activity is seen during non-REM sleep. The sleep-active
cells comprise about 25% of the recorded cells in the basal
forebrain-preoptic area and are intermixed with wake-active
cells which predominate. Thus, the activity of the sleep-active
neurons would release inhibitory agents at target wake-active
neurons, shutting them off and triggering sleep (McGinty and
Szymusiak, 2000). Lesions of the VLPO decrease sleep and
increase wake (Lu et al., 2000), thereby replicating Nauta’s and
von Economo’s observations. When the lesions extend dorsally
then REM sleep is decreased, suggesting that this region influ-
ences pontine REM sleep generator neurons. The VLPO and
MnPN neurons may become active in response to sleep pres-
sure (Gvilia et al., 2006a,b). The preoptic area sleep-active neu-
rons in the VLPO and MnPN may convey light-dark informa-
tion since they receive input from the retina (Lu et al., 1999).
Since the sleep-active neurons are in a minority and are nes-
tled with neurons regulating waking it is important to selec-
tively stimulate phenotypically identified GABA/galanin sleep-
active neurons. This will provide direct evidence linking them
to sleep generation. The new methods, such as optogenetics and
DREDD, enable selective manipulation of neurons, which is an
advantage over non-selective neuronal activation with electrical
studies.
NEURONS CONTAINING MELANIN CONCENTRATING HORMONE (MCH)
The sleep-active neurons in the preoptic area (VLPO and MnPN)
are still considered to be the only neurons responsible for
sleep in current models of sleep-wake regulation (Saper et al.,
2010).
However, sleep-active neurons outside the preoptic area have
been found (Jones, 2011). Some of these neurons contain melanin
concentrating hormone (MCH; Hassani et al., 2009). In head
restrained rats MCH neurons are quiet during waking, begin
firing during non-REM and are most active during REM sleep
(Hassani et al., 2009).
Mammalian MCH is a 19 amino acid hormone synthesized
as a prepro-hormone encoding two additional peptides neu-
ropeptide EI and neuropeptide GE (NGE) which are cleaved
by post-translational modification (Nahon, 1994). MCH neu-
rons co-express GABA (Elias et al., 2008), CART (cocaine- and
amphetamine-regulated transcript; Broberger, 1999), and nes-
fatin (Fort et al., 2008).
However, GABA, nesfatin and CART are also found in non-
MCH neurons. MCH expressing neurons are present in the
zona incerta, dorsomedial hypothamus and lateral hypothalamus
(Elias et al., 1998; See Figure 1). Overall, MCH neurons project
to the same targets as orexin neurons (Bittencourt and Elias,
1993, 1998; Elias and Bittencourt, 1997; Elias et al., 2008). MCH
neurons have been shown by in situ hybridization, to co-localize
with nociceptin/orphanin FQ opioid receptor (NOP), MCHR1,
both orexin receptors (ORX), somatostatin receptors 1 and 2
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FIGURE 1 | Distribution of MCH-immunoreactive neurons in wildtype
C57Bl6/j mice (3 months old). Coronal sections (40 µm thick) were
processed for immunohistochemical detection of MCH-immunoreactivity
(rabbit anti-MCH; 1:5000 dilution; overnight incubation) and visualized using
the avidin-biotin -diaminobenzidene method. The MCH-ir neurons were
present only in the hypothalamus (boxed area in photo A). A major cluster is
located in the zona incerta (photo B) and extends medially to the ventricle.
Another major cluster is located laterally (arrowheads in D). Minor clusters
are located around the fornix (photo C) and ventrally along the dorsal border
of the VMH (arrow in photo D). The numbers in (B–D) represent distance
(millimeters) caudal to bregma. The calibration bar in (D) = 250 µm.
Abbreviations: 3v= third ventricle; f = fornix; mt = mammillothalamic tract;
ot = optic tract; ZI = zona incerta.
(SSTR1, SSTR2), kisspeptin receptor (KissR1), neurotensin recep-
tor 1 (NTSR1), neuropeptide S receptor (NPSR), cholecystokinin
receptor A (CCKAR), and the κ-opioid receptor (Parks et al.,
2014b).
There are two MCH receptors, but only MCH receptor-1 is
present in rodents (Chambers et al., 1999; Tan et al., 2002).
MCHR1 is expressed in hippocampus, subiculum, basolateral
amygdala, shell of the nucleus accumbens, hypothalamus
(ventromedial nucleus, arcuate nucleus, and zona incerta),
TMN, dorsolateral pons, including the dorsal raphe, and
LC (Saito et al., 2001). MCH couples to the Gi alpha
subunit and inhibits production of cAMP (Saito et al.,
2001).
MCH knockout mice are awake and more active, have less non-
REM, and are lean (Zhou et al., 2005; Willie et al., 2008). MCHR1
knockout mice have overall normal sleep levels and a normal
sleep rebound after sleep deprivation (Adamantidis et al., 2008).
Transgenic mice overexpressing prepro-MCH are hyperphagic
and develop mild obesity with insulin-resistance (Ludwig et al.,
2001). Ablation of the MCH neurons (MCH-ataxin; 60–70%
loss) results in mice that are lean, hypophagic, having increased
temperature and energy expenditure (Alon and Friedman, 2006),
but sleep has not been recorded in these mice.
Effects of MCH on sleep
Intracerebroventricular (ICV) injection of MCH during the dark
period dose dependently increases REM sleep by 200% and non-
REM by 70% (Verret et al., 2003). MCH injection into sleep
promoting areas such as VLPO significantly increase non-REM
(Benedetto et al., 2013) while injection into REM sleep areas
such as nucleus pontis oralis or dorsal raphe increase REM sleep
(Torterolo et al., 2009; Lagos et al., 2011). Luppi’s group has
suggested that MCH neurons regulate REM sleep based on c-Fos
expression in MCH neurons after REM sleep deprivation (Verret
et al., 2003; Hanriot et al., 2007).
We have measured CSF levels of MCH in rats and find that
it is highest during the day when the rats have the most sleep
(Pelluru et al., 2013). In the same rats, orexin levels were highest at
night, which is when the rats are awake. In humans, MCH is also
associated with sleep and orexin with waking (Blouin et al., 2013).
Thus, orexin and MCH levels are reciprocal to each other just like
their firing pattern. They also have opposite effect on sleep-wake.
Pharmacology of MCH neurons (partial list; Figure 3)
MCH neurons are excited by orexin directly, and indirectly by
enhancing glutamate release from excitatory neurons synapsing
on MCH neurons (van den Pol et al., 2004; Huang and van den
Pol, 2007). MCH neurons are excited by AMPA agonists and
NMDA (van den Pol et al., 2004; Huang and van den Pol, 2007).
MCH neurons are also excited by cannabinoid type-1 receptor
(CB1R) agonist (Huang et al., 2007). This might explain the sleep-
inducing effects of marijuana (Huang et al., 2007).
The peptide MCH inhibits orexin neurons, an effect not seen
in MCHR1KO (Rao et al., 2008). MCH also inhibits neighboring
GABA neurons (Gao and van den Pol, 2001). MCH neurons
are inhibited by MCH, GABA, NE (effect mediated by alpha-2
receptor), serotonin, acetylcholine (muscarinic), Neuropeptide Y
(NPY; Gao et al., 2003; van den Pol et al., 2004) and Histamine
(Parks et al., 2014a). Dopamine (DA) inhibits MCH neurons
through alpha-2 receptor (Alberto et al., 2011) and also D1 and
D2 like receptors (Conductier et al., 2011).
Optogenetic activation of MCH neurons
The MCH neurons are virtually silent during waking, increase
their discharge rates during sleep and reach their peak activity
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during REM sleep (Hassani et al., 2009). Based on their activity
patterns we hypothesized that activating the neurons during wak-
ing should hasten sleep onset. To test this hypothesis we inserted
the gene for the light-sensitive cation channel, channelrhodopsin-
2, into MCH neurons in wildtype C57Bl6/j mice (Figure 2).
We chose not to use the MCH-Cre mice, which have limited
testing the hypothesis only in mice. Instead, we created our own
MCH-promoter driven vector (supplied by Anthony van den Pol)
to insert the ChR2+EYFP into MCH neurons in all vertebrate
species. Three weeks after gene insertion, we recorded sleep for
48 h and then stimulated the MCH neurons with 473 nm blue
light pulses (10 ms; 1 min on every 5 min; Konadhode et al.,
FIGURE 2 | Expression of ChR2-eYFP in MCH-immunoreactive neurons
in the lateral hypothalamus of a representative wildtype C57BL/6J
mouse. Compare with Figure 1. Panel (A) depicts the expression of
ChR2-eYFP (green) in MCH neurons (red). Notice that the MCH neurons are
diffusely distributed around the fornix and many MCH neurons located
medial and ventral to the fornix did not contain the light-sensitive opsin.
Panel (B) is a higher magnification view of a cluster of MCH neurons (arrow
in panel A) that also contain ChR2-EYFP. Panel (C) depicts the close
relationship between the orexin neurons (red) and MCH neurons (green
ChR2-eYFP). The arrows in panel (C) show the encirclement of an orexin
soma by MCH-ChR2-EYFP processes. Scale bar in (A) is 250 µm, (B) is 50
µm and (C) is 60 µm. Abbreviations: 3V = third ventricle; mt =
mammillothalamic tract; mfb = medial forebrain bundle; f = fornix; VMH =
ventromedial hypothalamus.
2013). The stimulation began at lights-off, which is the start of the
active phase of nocturnal rodents. We found that such stimulation
reduced the length of waking bouts and increased both non-REM
and REM sleep. The increase in sleep was most robust when the
lights pulses were given at 10 Hz compared to 0 Hz or 5 Hz.
The 10 Hz stimulation also increased delta power, a marker of
sleep intensity. We did not find that optogenetic activation of
MCH neurons during the light phase, which is the rest phase of
nocturnal rodents, had any effect on sleep. We concluded that
because the mice are normally asleep during the day it is not
possible to generate more sleep. In other words, during the light
phase there is a ceiling effect.
Another group (Jego et al., 2013) used MCH-Cre mice, and
used a different stimulation paradigm compared to ours. They
stimulated only during the second half of the light phase and
only once the mice entered into REM sleep. They found that
such stimulation during REM sleep prolonged the REM sleep
bout. They also used light-sensitive halorhodopsin, eNpHR3.0, to
inhibit the MCH neurons, but it did not abort REM sleep bouts.
They did not stimulate during waking or at night.
A third group expressed the gene for diphtheria toxin in the
MCH neurons to selectively kill the MCH neurons (Tsunematsu
et al., 2014). When the MCH neurons were ablated the mice
were awake more during the day and night and had a selective
decrease in non-REM sleep, but no change in amount of REM
sleep. That study also found that optogenetic stimulation of the
MCH neurons at night decreased the length of waking bouts at
night and increased the number of non-REM sleep bouts (Figures
2A,B in Tsunematsu et al., 2014). In their study inhibition of
the MCH neurons during the day had no effect on sleep, which
confirms what was found by Jego et al. (2013).
The difference between levels of non-REM and REM sleep
between the three studies might be related to activation of specific
population of MCH neurons. As seen in Figure 1 the MCH
neurons extend about 1 mm along the anterior posterior plane,
and are diffusely distributed about 1.5 mm laterally from the
midline, and about 1 mm along the dorsal-ventral plane. MCH
neurons are located densely in the zona incerta, in the lateral
portions of the lateral hypothalamus, along the perifornical area,
and ventrally along dorsal ridge of the ventromedial hypotha-
lamus. In our study ChR2 was robustly expressed in the MCH
neurons in the zona incerta, and less so in the lateral divisions
(see Figures 1, 2). Moreover, in our study, we stimulated about
half of the total population of MCH neurons, and found robust
increases in both non-REM and REM sleep. In particular, the
increase in sleep occurred against a strong waking drive indicating
that MCH neurons can suppress the combined activity of all of
the arousal neurons. The other two studies infected about 88%
of the MCH neurons but given the diffuse distribution of the
MCH neurons, and the fact that mammalian brain tissue heavily
scatters light so that only about 10% of light reaches to about
500 µm (Adamantidis et al., 2007; Aravanis et al., 2007), it is very
difficult to reliably stimulate all MCH+ChR2-positive neurons
with optogenetics. Nevertheless, these three studies underscore
the importance of MCH neurons in both non-REM and REM
sleep. It is likely that a pharmacogenetic approach with DREDD
may reach all the MCH neurons. However, the drawback of
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DREDD is that it is short-lived (because of half-life of the drug),
and does not provide millisecond control of targeted neurons.
The MCH peptide is inhibitory and inhibits orexin neurons
(Rao et al., 2008). It also inhibits neighboring GABA neurons
(Gao and van den Pol, 2001). MCH neurons also co-express
GABA. Thus, both MCH and GABA are likely to inhibit target
neurons. Thus, it is not surprising that activation of MCH neu-
rons is able to shut-off the arousal neurons and induce sleep.
When they are lost, as in the Tsunematsu et al. (2014) study,
then the orexin neurons are likely to be more active resulting in
increasing waking.
MCH has been implicated in feeding but optogenetic activa-
tion of MCH neurons induced sleep, not feeding (Jego et al., 2013;
Konadhode et al., 2013). In our study, we found that mice slept
rather than eat at a circadian time point when they normally
should be eating (Konadhode et al., 2013). In our study, the
mice had satiated their sleep need and undoubtedly were hungry.
Nevertheless, they slept in response to MCH neuron stimulation.
However, normal sucrose preference was reversed to sucralose
in response to 20 Hz optogenetic stimulation of MCH neurons
(Domingos et al., 2013).
Theoretical framework for the regulation of wake, non-REM and
REM sleep
Based on data from optogenetics, c-Fos, electrophysiology, and
lesion studies we hypothesize that sleep begins with activity
of the sleep-active neurons (preoptic and MCH). The MCH
neurons prevent the activation of the local orexin neurons which
likely decreases orexin’s drive of downstream arousal neurons.
The preoptic sleep-active neurons are also inhibiting the arousal
neurons. REM sleep occurs when the sleep-active neurons inhibit
GABA neurons in the pons (see our model for REM sleep in
Kaur et al., 2009) which then allows REM sleep-active neurons
to fire and REM sleep ensues. We hypothesize that sleep ends
because the MCH neurons are self-inhibiting and the wake state
ends when the orexin neurons activate the MCH neurons (see
Figure 3). There is support for this possibility because we find
that with MCH stimulation length of wake bouts is cut in half
but the length of non-REM or REM sleep bouts is unchanged.
We suggest that this is because with progressive activity MCH
neurons shut-off (self-inhibiting) and non-REM sleep ends. The
interaction between the MCH and orexin neurons still needs to
be investigated, but it provides a heuristic model of sleep-wake
regulation.
Our position based on existing data is that the MCH neurons
are a separate sleep promoting group that partners with the
preoptic sleep-active neurons in generating sleep. Can sleep occur
without the MCH neurons? Yes, since the preoptic area sleep-
active neurons are intact. Which dominates: preoptic or MCH
neurons? We think that each influences sleep based on their
input. For instance, preoptic sleep-active neurons receive direct
input from retina (Lu et al., 1999), are entrained to the light-
dark cycle and could control timing of sleep. MCH neurons are
within an area serving energy metabolism and respond to glucose
FIGURE 3 | MCH/GABA neurons are antagonistic to the orexin neurons.
We hypothesize that local interaction between these two opposing neurons
regulate sleep and wake. Glia are also likely to interact with neurons along the
lines hypothesized by Haydon’s studies. Abbreviations: Gamma-Aminobutyric
acid (GABA); Norepinephrine (NE); Serotonin (5-HT); Acetylcholine (Ach);
Dopamine (DA); Neuropeptide Y (NPY); Corticotropin releasing factor (CRF);
Cocaine-Amphetamine-Regulated Transcript (CART); Neuronal activity
regulated pentraxin (Narp).
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(Burdakov et al., 2005). Both the MCH and the hypocretin/orexin
neurons are located in a region sensing energy metabolism. A rise
in glucose activates MCH neurons (Burdakov et al., 2005; Kong
et al., 2010), which may explain post-prandial sleep.
CONCLUSIONS
More work needs to be done to fully identify the interaction
between the sleep-active and arousal neurons in regulating sleep
and wake. Important questions remain. For instance: How does
the suprachiasmatic nucleus regulate these neurons? What is the
relationship of energy metabolism and sleep-wake neurons? It is
also important to mechanistically demonstrate that turning on
sleep-active neurons shuts-off the wake-active neurons. This can
now be done with optogenetics, a powerful tool that allows the
neuroscientist to selectively manipulate specific neurons.
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